Abbott Laboratories is primarily active in the healthcare industry.

The main competitors of Abbott Laboratories in the market are Johnson & Johnson, Pfizer, and Roche Holding AG.

Abbott Laboratories is a renowned American healthcare company, known for providing a diverse range of medical, pharmaceutical, and nutritional products. Founded in 1888 by Dr. Wallace C. Abbott, the company initially focused on producing pharmaceuticals, including the widely successful alkaloid-based pain reliever, Abbott's ABC Liniment. Over the years, Abbott Laboratories has expanded its portfolio, venturing into areas such as diagnostics, medical devices, and nutrition. The company's commitment to innovation is evident through breakthroughs like the development of the first HIV blood-screening test. Today, Abbott Laboratories continues to play a crucial role in improving health outcomes worldwide, with its cutting-edge technology and a focus on delivering quality healthcare solutions.

Abbott Laboratories has achieved several significant milestones throughout its history. One major milestone was the development and commercialization of the first-ever HIV blood screening test, which greatly contributed to safer transfusions and the prevention of the spread of HIV. Additionally, Abbott Laboratories introduced breakthrough medical devices, such as the FreeStyle® Libre system, a continuous glucose monitoring system for diabetes management. The company also played a crucial role in the fight against COVID-19 by developing rapid diagnostic tests for the virus. Furthermore, Abbott Laboratories has consistently been recognized for its commitment to innovation and sustainability, making it a leading healthcare company globally.

Abbott Laboratories is primarily present in multiple countries and regions worldwide. The company operates in more than 160 countries, including the United States, Canada, Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global footprint, Abbott Laboratories has established itself as a leading healthcare company in various markets, delivering innovative medical products, diagnostics, nutritionals, and pharmaceuticals to improve people's health and well-being.

Abbott Laboratories is committed to its core values of putting patients first, serving customers with innovative solutions, and operating with integrity in all aspects of its business. The company's corporate philosophy centers around improving life through the development of groundbreaking technologies and products. Abbott Laboratories prides itself on its dedication to delivering reliable healthcare solutions, fostering collaboration with healthcare professionals, and investing in research and development to address unmet medical needs. With a focus on providing high-quality and accessible healthcare options, Abbott Laboratories strives to create positive impacts in communities worldwide through its diverse portfolio of medical devices, diagnostics, nutrition, and pharmaceutical products.

Analysts currently set an average price target of 136,02 USD for the Abbott Laboratories stock (median: 137,70 USD), implying +28,5 % versus the latest price. The consensus is based on 35 analyst ratings.

Abbott Laboratories Koersdoelstellingen analisten 2026

35 analysts currently rate the Abbott Laboratories stock: 25 recommend buying, 10 holding and 0 selling. For 2026, analysts expect Abbott Laboratories to generate revenue of 50,29 Miljard USD and earnings per share of 5,51 USD.

Abbott Laboratories Koersdoelstellingen analisten 2026

Converted at the current exchange rate, the Abbott Laboratories share trades at 90,56 EUR (104,38 USD).

The Abbott Laboratories share (ABT) is listed on 9 stock exchanges, including: NYSE (ABT), XETRA (ABL.DE), Frankfurt (ABL.F), München (ABL.MU), Düsseldorf (ABL.DU), Hamburg (ABL.HM), London (0Q15.L), SIX (Zürich) (ABT.SW).

Abbott Laboratories is a global company specializing in the development, manufacturing, and marketing of health products and services. Its business model is divided into different divisions that focus on the needs of patients, doctors, and healthcare systems. The divisions of Abbott Laboratories include Diagnostics, Medical Devices, Nutrition, and Pharmaceutical. The company aims to continuously develop innovative technologies and products to improve healthcare, and it offers a wide range of services and support programs for patients. Abbott Laboratories has established a strong market position and global presence in over 160 countries since its establishment in 1888. It also pursues a successful acquisition strategy to expand its product portfolio, such as the acquisition of St. Jude Medical in 2017 to enhance its cardiovascular products and services. Overall, Abbott Laboratories aims to improve healthcare and meet the needs of patients, doctors, and healthcare systems through its comprehensive strategy focused on developing innovative products, expanding into new markets, and increasing efficiency.

De verwachte omzet van Abbott Laboratories bedraagt 50,29 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De verwachte winst van Abbott Laboratories bedraagt 9,63 Miljard USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van Abbott Laboratories bedraagt momenteel 18,93. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Abbott Laboratories-aandeel in te schatten.

De koers-omzetverhouding (P/S) van Abbott Laboratories bedraagt momenteel 3,63. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Abbott Laboratories-aandeel.

De Eulerpool Kwaliteitsscore voor Abbott Laboratories is 6/10.

De ISIN van Abbott Laboratories is US0028241000. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van Abbott Laboratories is 850103. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van Abbott Laboratories is ABT. Onder dit beurstickersymbool wordt het Abbott Laboratories-aandeel op de beurs verhandeld.

Binnen de laatste 12 maanden betaalde Abbott Laboratories een dividend van 2,36 USD . Dit komt overeen met een dividendrendement van ongeveer 2,26 %. Voor de komende 12 maanden zal Abbott Laboratories naar verwachting een dividend van 2,76 USD betalen.

De dividendrendement van Abbott Laboratories is momenteel 2,26 %.

Abbott Laboratories betaalt een dividend uit, dat wordt uitgekeerd in de maanden , , , .

Abbott Laboratories betaalde de afgelopen 52 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 2,76 USD verwacht. Dit komt overeen met een dividendrendement van 2,61 %.

Abbott Laboratories wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Abbott Laboratories van ter hoogte van 0,63 USD te ontvangen, moest je het aandeel voor de ex-datum op in je portefeuille hebben.

De laatste dividenduitkering vond plaats op .

In het jaar 2025 heeft Abbott Laboratories 2,24 USD aan dividenden uitgekeerd.

De dividenden van Abbott Laboratories worden in USD uitgekeerd.